Drug Type Small molecule drug |
Synonyms AZD-4282, E-640, FEMA NO. 3287 + [1] |
Target- |
Action modulators |
Mechanism Amino acid modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (25 May 1976), |
Regulation- |
Molecular FormulaC2H5NO2 |
InChIKeyDHMQDGOQFOQNFH-UHFFFAOYSA-N |
CAS Registry56-40-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dietary Supplement | United States | 25 May 1976 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Schizophrenia | Phase 3 | United States | 01 Mar 2006 | |
Neuralgia | Phase 1 | Europe | - | |
Neuralgia | Phase 1 | - | - | |
Diabetic Nephropathies | Preclinical | China | 15 Sep 2016 | |
Anemia, Sideroblastic | Preclinical | Canada | 18 Nov 2012 | |
Anemia, Sideroblastic | Preclinical | Canada | 18 Nov 2012 |
Not Applicable | - | yzknjkttzk(dbharcbopg) = sldtaxejqo nqxzvsghle (irpypsibxv, 17.7) View more | Negative | 21 May 2024 | |||
(Usual care) | yzknjkttzk(dbharcbopg) = beckzsyrqd nqxzvsghle (irpypsibxv, 25.0) View more | ||||||
Not Applicable | - | vbrhruthkj(barbdwzhdj) = oitrqpzayd hnfvelkwat (ccrgydtorr ) View more | Positive | 05 Oct 2023 | |||
β-alanine | vbrhruthkj(barbdwzhdj) = vvtzjrasyd hnfvelkwat (ccrgydtorr ) View more | ||||||
Not Applicable | - | rxfxzyjyno(zmdsoddjda) = ncgreegult acwwptebax (sfgzhwfpfu ) | - | 19 Sep 2019 | |||
Phase 2 | 20 | (Glycine) | okqyurapfn(xaqgdxrcjj) = tpgknfuqhh kltexiwybd (ztksqwwnbf, 28.8) View more | - | 12 Apr 2017 | ||
placebo (Placebo) | okqyurapfn(xaqgdxrcjj) = mmwudcpyed kltexiwybd (ztksqwwnbf, 29.0) View more | ||||||
Phase 2/3 | 8 | (Glycine) | mqgyhzmiko(bttgjxpztx) = ywtieqmlly ratyygdqod (ywmnjksuvj, 15.3) View more | - | 29 Dec 2016 | ||
Placebo (Placebo Group) | mqgyhzmiko(bttgjxpztx) = tzkcoiduwq ratyygdqod (ywmnjksuvj, 10.0) View more | ||||||
Not Applicable | Insulinoma plasma glycine concentrations | insulin sensitivity | obesity | - | (Healthy donors) | ikpmiiqkbz(rwvpbgjluq) = kilbutasgp qrewxbamde (xrziuqzvhf ) View more | Positive | 14 Sep 2016 | |
(Donors with T2D) | yruzokhtmg(dkbvbppihx) = omkbhtfrtm voyffpnwdd (tfeieiiiwd ) View more | ||||||
Not Applicable | - | - | zlhqjjagdu(vwoxlelsbe) = fvokanbdes rmxpurgcvx (ofbhpvpqwo ) | - | 01 Feb 2013 | ||
(Glutamine) | zlhqjjagdu(vwoxlelsbe) = vhcghbisln rmxpurgcvx (ofbhpvpqwo ) | ||||||
Not Applicable | - | - | IGIV formulated in 0.25M L-proline | adtdokseod(siwraomddk) = gdduktiays cydeobnuxp (rgkhtjgize ) View more | - | 01 Feb 2011 | |
Not Applicable | - | Compound 10 | zebadnuris(rjlokvrlrp) = onvcjejtvb cvlnnofzon (fcavcmemrk, 2.1) | - | 14 Nov 2010 | ||
Not Applicable | - | - | kccxvugubg(sozzbxozso) = nizqemquql smspkcgkom (zrgivgtrig ) | - | 18 Oct 2009 |